美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Vicore Pharma Holding AB

11.38

-0.0100-0.09%

盘后：11.35-0.0300-0.26%17:27 EDT

成交量：1,477

成交额：1.69万

市值：3.20亿

市盈率：-57.42

高：11.42

开：11.42

低：11.38

收：11.39

52周最高：17.80

52周最低：11.00

股本：2,815.26万

流通股本：1,986.21万

量比：0.58

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.1982

每股收益(LYR):-0.2159

净资产收益率：-47.19%

总资产收益率：-28.12%

市净率：3.14

市盈率(LYR):-52.70

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Vicore Pharma Holding AB

交易所：

NASDAQ

成立时间：

2000

员工人数：

40

公司地址：

Kornhamnstorg 53,Stockholm,Stockholm County,Sweden

官网：

http://www.vicorepharma.com

邮编：

111 27

电话：

46 3 17 88 05 60

传真：

- -

简介：

Vicore Pharma Holding AB于2005年根据瑞典法律注册成立为一家股份有限公司。该公司是一家临床阶段的制药公司，致力于开发呼吸系统疾病和纤维化疾病的治疗药物。其主要候选产品buloxibutid (C21)是一种口服小分子血管紧张素II 2型受体激动剂，已获得美国食品药品监督管理局的孤儿药资格认定和快速通道资格认定，目前正在进行一项针对特发性肺纤维化的全球IIb期临床试验。该公司的药物研发项目基于AT2受体，AT2受体是肾素-血管紧张素系统的一部分，该系统是一种调节血压和水平衡的激素系统。

董事

名称

职位

Hans Schikan

Chairman and Director

Ann Barbier

Independent Director

Elisabeth Björk

Independent Director

Heidi Hunter

Independent Director

Jacob Gunterberg

Independent Director

Peter Guenter

Independent Director

Yasir Al Wakeel

Independent Director

股东

名称

职位

Ahmed Mousa

Chief Executive Officer

Hans Jeppsson

Chief Financial Officer

Bernt van den Blink

Chief Medical Officer

Rob Slack

Chief Scientific Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/VCRE/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VCRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VCRE\",,,,,undefined,":{"symbol":"VCRE","market":"US","secType":"STK","nameCN":"Vicore Pharma Holding AB","latestPrice":11.38,"timestamp":1784923200000,"preClose":11.39,"halted":0,"volume":1477,"hourTrading":{"tag":"盘后","latestPrice":11.35,"preClose":11.38,"latestTime":"17:27 EDT","volume":645,"amount":7292.65,"timestamp":1784928435427,"change":-0.03,"changeRate":-0.002636,"amplitude":0.002636},"delay":0,"changeRate":-0.0008779631255487082,"floatShares":19862100,"shares":28152600,"eps":-0.198177,"marketStatus":"休市中","change":-0.01,"latestTime":"07-24 16:00:00 EDT","open":11.42,"high":11.42,"low":11.38,"amount":16850,"amplitude":0.003512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.198177,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":11.39,"preHourTrading":{"tag":"盘前","latestPrice":11.45,"preClose":11.39,"latestTime":"09:16 EDT","volume":313,"amount":3595.448841,"timestamp":1784899009972,"change":0.06,"changeRate":0.005268,"amplitude":0.011414},"postHourTrading":{"tag":"盘后","latestPrice":11.35,"preClose":11.38,"latestTime":"17:27 EDT","volume":645,"amount":7292.65,"timestamp":1784928435427,"change":-0.03,"changeRate":-0.002636,"amplitude":0.002636},"volumeRatio":0.5784265485758022},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VCRE\",,,,,undefined,":{"symbol":"VCRE","floatShares":19862100,"roa":"-28.12%","roe":"-47.19%","lyrEps":-0.215948,"volumeRatio":0.5784265485758022,"shares":28152600,"dividePrice":0,"high":11.42,"amplitude":0.003512,"preClose":11.39,"low":11.38,"week52Low":11.0001,"pbRate":"3.14","psRate":"882.82","week52High":17.8,"institutionHeld":0,"latestPrice":11.38,"eps":-0.198177,"divideRate":0,"volume":1477,"delay":0,"ttmEps":-0.198177,"open":11.42,"prevYearClose":14.9,"prevWeekClose":11.82,"prevMonthClose":14.9,"prevQuarterClose":14.9,"fiveDayClose":11.82,"earningDate":1787241600000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VCRE\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"VCRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787299200000,"name":null,"time":"盘前","dateTimestamp":1787284800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VCRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VCRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.625,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1774411200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VCRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VCRE","date":"2026-07-24","current":-57.423414,"percent":0.928571,"low":-9.302023,"twenty":-7.681287,"median":-6.881598,"eighty":-6.732101,"high":-6.632437,"avg":-7.240707,"sd":0.714961,"marketCap":323298529.11},"quantilePoints":[{"date":"2026-07-10","current":-7.569758,"twenty":-8.26741,"median":-7.937568,"eighty":-7.607725,"marketCap":371834447.2},{"date":"2026-07-17","current":-6.73922,"twenty":-7.951806,"median":-7.409583,"eighty":-6.864987,"marketCap":331740814.59},{"date":"2026-07-24","current":-6.656167,"twenty":-7.681287,"median":-6.881598,"eighty":-6.732101,"marketCap":323298529.11}],"updateTime":1784986310406},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1427456,"yearFounded":2000,"employeeNum":40,"address":"Kornhamnstorg 53,Stockholm,Stockholm County,Sweden","zipCode":"111 27","officePhone":"46 3 17 88 05 60","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.vicorepharma.com","stockEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":-0.2362},{"period":"ytd","weight":-0.2362}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vicore Pharma Holding AB于2005年根据瑞典法律注册成立为一家股份有限公司。该公司是一家临床阶段的制药公司，致力于开发呼吸系统疾病和纤维化疾病的治疗药物。其主要候选产品buloxibutid (C21)是一种口服小分子血管紧张素II 2型受体激动剂，已获得美国食品药品监督管理局的孤儿药资格认定和快速通道资格认定，目前正在进行一项针对特发性肺纤维化的全球IIb期临床试验。该公司的药物研发项目基于AT2受体，AT2受体是肾素-血管紧张素系统的一部分，该系统是一种调节血压和水平衡的激素系统。","exchange":"NASDAQ","name":"Vicore Pharma Holding AB","nameEN":"Vicore Pharma Holding AB"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VCRE\",market:\"US\",,,undefined,":{"directors":[{"name":"Hans Schikan","position":"Chairman and Director"},{"name":"Ann Barbier","position":"Independent Director"},{"name":"Elisabeth Björk","position":"Independent Director"},{"name":"Heidi Hunter","position":"Independent Director"},{"name":"Jacob Gunterberg","position":"Independent Director"},{"name":"Peter Guenter","position":"Independent Director"},{"name":"Yasir Al Wakeel","position":"Independent Director"}],"executives":[{"name":"Ahmed Mousa","position":"Chief Executive Officer"},{"name":"Hans Jeppsson","position":"Chief Financial Officer"},{"name":"Bernt van den Blink","position":"Chief Medical Officer"},{"name":"Rob Slack","position":"Chief Scientific Officer"}]}}}